Elevated S100A6 (Calcyclin) enhances tumorigenesis and suppresses CXCL14-induced apoptosis in clear cell renal cell carcinoma
Metrics: PDF 1407 views | HTML 1720 views | ?
Xiang-Jun Lyu1,*, Hong-Zhao Li1,*, Xin Ma1, Xin-Tao Li1, Yu Gao1, Dong Ni2, Dong-Lai Shen1, Liang-You Gu1, Bao-Jun Wang1, Yu Zhang1, Xu Zhang1
1Department of Urology/State Key Laboratory of Kidney Diseases, Chinese People's Liberation Army General Hospital/PLA Medical School, Beijing, People's Republic of China
2Department of Urology, Zhongnan Hospital, Wuhan University, Wuhan, People's Republic of China
*These authors have contributed equally to this work
Xu Zhang, e-mail: email@example.com
Keywords: clear cell renal cell carcinoma, tumorigenesis, S100A6, CXCL14, apoptosis
Received: December 11, 2014 Accepted: January 18, 2015 Published: February 03, 2015
Clear cell renal cell carcinoma (ccRCC) is often resistant to existing therapy. We found elevated S100A6 levels in ccRCC tissues, associated with higher grade pathological features and clinical stages in ccRCC patients. Knockdown of S100A6 inhibited cell proliferation in vitro and tumor growth in vivo. Gene expression profiling suggests a novel function of S100A6 in suppressing apoptosis, as well as a relationship between S100A6 and CXCL14, a pro-inflammatory chemokine. We suggest that the S100A6/CXCL14 signaling pathway is a potential therapeutic target in ccRCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.